Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

TaiGen Sells Russian Rights for Lead Antibiotic

publication date: Jan 15, 2014
TaiGen Biotechnology of Taiwan and Beijing has out-licensed Russian rights for its novel antibiotic to R-Pharm, a major drug company in Russia. The antibiotic – nemonoxacin – treats bacterial infections including those caused by drug-resistant bacteria. TaiGen will receive an upfront payment, milestones and royalties on sales, though specific amounts were not disclosed. R-Pharm will be responsible for registration and commercialization of nemonoxacin in Russia, former Soviet countries and Turkey. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital